首页> 外文OA文献 >The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers
【2h】

The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers

机译:RNA解旋酶/转录共调节因子p68(DDX5)刺激致癌蛋白激酶Polo样激酶1(PLK1)的表达,并与人乳腺癌中PLK1水平升高相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

p68 (DDX5) acts both as an ATP-dependent RNA helicase and as a transcriptional co-activator of several cancer-associated transcription factors, including the p53 tumor suppressor. p68 is aberrantly expressed in a high proportion of cancers, but the oncogenic drive for, or the consequences of, these expression changes remain unclear. Here we show that elevated p68 expression in a cohort of human breast cancers is associated significantly with elevated levels of the oncogenic protein kinase, Polo-like kinase-1 (PLK1). Patients expressing detectable levels of both p68 and PLK1 have a poor prognosis, but only if they also have mutation in the TP53 gene (encoding p53), suggesting that p68 can regulate PLK1 levels in a manner that is suppressed by p53. In support of this hypothesis, we show that p68 stimulates expression from the PLK1 promoter, and that silencing of endogenous p68 expression downregulates endogenous PLK1 gene expression. In the absence of functional p53, p68 stimulates the expression of PLK1 both at basal levels and in response to the clinically relevant drug, etoposide. In keeping with a role as a transcriptional activator/co-activator, chromatin immuno-precipitation analysis shows that p68 is associated with the PLK1 promoter, irrespective of the p53 status. However, its recruitment is stimulated by etoposide in cells lacking p53, suggesting that p53 can oppose association of p68 with the PLK1 promoter. These data provide a model in which p68 and p53 interplay regulates PLK1 expression, and which describes the behavior of these molecules, and the outcome of their interaction, in human breast cancer. © 2014 Landes Bioscience.
机译:p68(DDX5)既作为ATP依赖的RNA解旋酶,又作为几种与癌症相关的转录因子(包括p53肿瘤抑制因子)的转录共激活因子。 p68在高比例的癌症中异常表达,但这些表达变化的致癌驱动力或后果尚不清楚。在这里,我们显示人类乳腺癌队列中p68表达的升高与致癌蛋白激酶Polo样激酶1(PLK1)的升高水平显着相关。表达可检测水平的p68和PLK1的患者预后较差,但前提是他们的TP53基因也有突变(编码p53),这表明p68可以通过p53抑制的方式调节PLK1水平。为支持该假设,我们表明p68刺激了PLK1启动子的表达,而内源性p68表达的沉默下调了内源性PLK1基因的表达。在缺乏功能性p53的情况下,p68会在基础水平和对临床相关药物依托泊苷的反应中均刺激PLK1的表达。染色质免疫沉淀分析显示,作为p68激活状态的转录激活因子/共激活因子,p68与PLK1启动子相关。然而,它的募集受到缺乏p53的细胞中依托泊苷的刺激,表明p53可以阻止p68与PLK1启动子的结合。这些数据提供了一个模型,其中p68和p53相互作用调节PLK1表达,并描述了这些分子在人类乳腺癌中的行为及其相互作用的结果。 ©2014 Landes Bioscience。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号